Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line

• Published in: Oncology letters Vol. 17; no. 2; pp. 2431 - 2440
• Main Authors: Fujita, Hiromasa, Hirose, Katsumi, Sato, Mariko, Fujioka, Ichitaro, Fujita, Tamaki, Aoki, Masahiko, Takai, Yoshihiro
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.02.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Adenosine monophosphate; Antidiabetics; Antineoplastic agents; Cancer; Cancer therapies; Cancer treatment; Cell cycle; Chemoembolization; Chemotherapy; Diabetes therapy; Dose-response relationship; Drug dosages; Drug therapy; Hypoglycemic agents; Hypoxia; Liver; Liver cancer; Metastasis; Metformin; Methods; Necrosis; Neoadjuvant therapy; Oncology; Patient outcomes; Penicillin; Protein kinases; Surgery; Therapeutic embolization; Tumors; Type 2 diabetes; Veins & arteries; United States > US; Japan; hepatoblastoma; hypoxia; metformin; liver cancer; cisplatin; transarterial chemoembolization; HepG2 cell
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2018.9869

Hepatoblastoma is the most commonly occurring liver tumor in children. Preoperative chemotherapy and surgery have improved treatment outcomes; however, further improvements are required in the treatment of advanced cases. Recently, the efficacy of transarterial chemoembolization (TACE) has garnered attention. TACE increases the local concentration of drugs by transcatheterically administering antitumor agents, and induces necrosis in the tumor by embolizing the feeding artery. However, studies have revealed that tumors exhibit resistance to anticancer drugs in hypoxic environments. Metformin is a drug used to treat type 2 diabetes; however, recent reports have indicated that it may also exhibit antitumor effects in various cancer cell lines. These effects are hypothesized to be mediated by the activation of adenosine monophosphate-activated protein kinase and reduction of mammalian target of rapamycin signaling, but these effects occur at high concentrations that are not suitable for use in a clinical setting. The potential efficacy of metformin at increased physiological concentrations has not been evaluated. The present study investigated the therapeutic effect of low concentrations of metformin in combination with cisplatin on liver cancer HepG2 cells in hypoxic conditions. HepG2 cells were treated with cisplatin alone, metformin alone, or a combination of these two drugs and cultured in normoxia or hypoxia. Treatment with either 5 µM cisplatin or 1 mM metformin alone did not significantly affect cell proliferation or apoptosis in hypoxic conditions. However, when 5 µM cisplatin was combined with 1 mM metformin, a significant inhibition of cell proliferation and induction of apoptosis was observed in hypoxic HepG2 cells. In conclusion, a low concentration of metformin attenuates hypoxia-induced resistance to cisplatin in HepG2 cells. Selective delivery of an effective dose of metformin to a hepatoblastoma tumor may be achievable and clinically useful with TACE.